Baker Bros. Advisors LP
- SEC CIK
- 0001263508
- Latest filing
- Aug 14, 2026
BCRX holding history
Biocryst Pharmaceuticals Inc in every 13F filed by Baker Bros. Advisors LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
BCRX overviewAll 13F holders of BCRXFull Q2 2026 holdings
- Shares (Q1 2026)
- 0
- Sold out in Q1 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 16
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2026 | 0 | $0 | 0.0% | −2,822,727−100.0% | Sold out | Holders |
| Q4 2025 | 2,822,727 | $22.0M | 0.1% | +2,822,727 | New | Holders |
| Q4 2024 | 0 | $0 | 0.0% | −75,778−100.0% | Sold out | Holders |
| Q3 2024 | 75,778 | $575.9K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2024 | 75,778 | $468.3K | <0.1% | −10,050,398−99.3% | Reduced | Holders |
| Q1 2024 | 10,126,176 | $51.4M | 0.6% | 00.0% | Unchanged | Holders |
| Q4 2023 | 10,126,176 | $60.7M | 0.7% | −2,584,642−20.3% | Reduced | Holders |
| Q3 2023 | 12,710,818 | $90.0M | 0.5% | 00.0% | Unchanged | Holders |
| Q2 2023 | 12,710,818 | $89.5M | 0.5% | 00.0% | Unchanged | Holders |
| Q1 2023 | 12,710,818 | $106.0M | 0.6% | 00.0% | Unchanged | Holders |
| Q4 2022 | 12,710,818 | $145.9M | 0.9% | 00.0% | Unchanged | Holders |
| Q3 2022 | 12,710,818 | $160.2M | 1.0% | 00.0% | Unchanged | Holders |
| Q2 2022 | 12,710,818 | $134.5M | 0.8% | 00.0% | Unchanged | Holders |
| Q1 2022 | 12,710,818 | $206.7M | 1.2% | 00.0% | Unchanged | Holders |
| Q4 2021 | 12,710,818 | $176.0M | 0.9% | 00.0% | Unchanged | Holders |
| Q3 2021 | 12,710,818 | $182.7M | 0.8% | 00.0% | Unchanged | Holders |
| Q2 2021 | 12,710,818 | $201.0M | 0.9% | 00.0% | Unchanged | Holders |
| Q1 2021 | 12,710,818 | $129.3M | 0.6% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.